North America Alpha and Beta Emitters Based Radiopharmaceuticals Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Alpha and Beta Emitters Based Radiopharmaceuticals Market Size

• The North America alpha and beta emitters based radiopharmaceuticals market size was valued at USD 339.33 million in 2024 and is expected to reach USD 783.52 million by 2032, at a CAGR of 11.1% during the forecast period
• The market growth is largely fueled by the increased efficacy of targeted alpha and beta therapies
• Furthermore, growing adoption of theranostics in personalized medicine. These converging factors are accelerating the uptake of alpha and beta emitters based radiopharmaceuticals solutions, thereby significantly boosting the industry's growth

Alpha and Beta Emitters Based Radiopharmaceuticals Market Analysis

• Alpha and beta emitters based radiopharmaceuticals are increasingly recognized for their precision in targeted therapy, especially in oncology and nuclear medicine, providing effective diagnosis and treatment options with minimal side effects
• The rising incidence of cancer worldwide, along with growing awareness about personalized medicine and advancements in radiopharmaceutical technology, is driving North America demand for alpha and beta emitters based radiopharmaceuticals
• U.S. holds a significant share in the alpha and beta emitters based radiopharmaceuticals market, accounting for approximately 44.52% of the revenue in 2025, supported by advanced healthcare infrastructure, extensive R&D activities, and early adoption of novel therapeutic technologies
• U.S. is anticipated to be the fastest-growing market for alpha and beta emitters based radiopharmaceuticals during the forecast period, propelled by expanding healthcare infrastructure, increasing cancer prevalence, government initiatives for healthcare improvement
• The beta emitters segment is expected to dominate the market with a share of 83.70% in 2025, driven by their high efficacy in Targeted Alpha Therapy (TAT), improved patient outcomes, and rising research focused on alpha-emitting isotopes like Actinium-225 and Radium-223 for cancer treatment

Report Scope and Alpha and Beta Emitters Based Radiopharmaceuticals Market Segmentation  

Alpha and Beta Emitters Based Radiopharmaceuticals Market Trends

“Increased Efficacy of Targeted Alpha and Beta Therapies”

• A major driving force behind the North America alpha and beta emitters based radiopharmaceuticals market is the increasing clinical adoption of targeted radionuclide therapies, owing to their proven efficacy in treating advanced cancers such as neuroendocrine tumors and metastatic castration-resistant prostate cancer (mCRPC)
• For instance, in May 2023, according to the article published by NCBI, the approved [177Lu]Lu-PSMA-617 regimen (7.4 GBq per cycle every 6 weeks for up to 6 cycles) has shown strong safety and anti-tumor efficacy in real-world use, with flexible dosing (6–9.3 GBq) and treatment intervals (4–10 weeks). This consistent clinical performance enhances physician confidence and accelerates market adoption
• Radiopharmaceuticals like Lu-177, particularly when used in peptide receptor radionuclide therapy (PRRT), have demonstrated remarkable success in the treatment of neuroendocrine tumors, delivering potent beta radiation directly to tumor sites while preserving healthy tissues—leading to improved outcomes and increased demand
• Technological advancements and clinical validation of alpha-emitting isotopes, such as Ac-225, have further propelled the market. Ac-225 has proven highly effective in targeting prostate cancer cells resistant to traditional therapies, with minimal side effects and strong therapeutic impact

Alpha and Beta Emitters Based Radiopharmaceuticals Market Dynamics

Driver

“Growing Adoption of Theranostics in Personalized Medicine”

• The increasing adoption of theranostic alpha- and beta-emitter radiopharmaceuticals—such as Lutetium-177 (Lu-177) and Terbium-161 (Tb-161)—is a major driver propelling the North America radiopharmaceuticals market. By pairing diagnostic imaging with targeted therapy in a single clinical workflow, these agents deliver precise, patient-specific care that improves outcomes and streamlines treatment planning
• For instance, in July 2023, a review published in NCBI reported rising clinical use of Lu-177–based theranostic regimens (e.g., ¹⁷⁷Lu-DOTATATE for neuroendocrine tumors and ¹⁷⁷Lu-PSMA for prostate cancer). FDA approvals for these agents validated their safety and efficacy, accelerating adoption and highlighting the powerful synergy of matched diagnostic–therapeutic pairs
• Growing awareness among oncologists and nuclear-medicine specialists of the workflow efficiency, treatment accuracy, and reduced toxicity associated with theranostic approaches is driving demand, as clinicians seek reliable tools for personalized cancer management.
• Furthermore, as healthcare systems face mounting pressures to improve survival rates and control costs, integrated imaging-therapy solutions like Lu-177 and Tb-161 reduce time to treatment, avoid ineffective interventions, and enhance quality of life—solidifying their value proposition
• The rising preference for precision oncology, coupled with ongoing R&D in next-generation isotopes such as Tb-149, Tb-152/155, and Ac-225, positions theranostic radiopharmaceuticals as a cornerstone of modern cancer care and a key growth engine for the North America market

Restraint/Challenge

“Supply Chain and Scalability Challenges from Short Isotope Half-Lives”

• The short half-life of radionuclides such as Lead-212 (~10.6 hours) creates major logistical and operational hurdles: production must occur close to treatment sites, transport windows are only a few hours, and highly coordinated “just-in-time” supply chains are required—collectively constraining large-scale manufacturing and market reach
• For instance, in April 2025 L.E.K. Consulting noted that Pb-212’s 10.6-hour half-life forces decentralized, near-patient production and on-site generator infrastructure, limiting economies of scale and complicating distribution logistics
• Furthermore, the intricate generator systems needed to extract Pb-212 (and other short-lived isotopes) add layers of regulatory compliance, radiation-safety requirements, and capital expenditure, making broad deployment difficult for hospitals and radiopharmacies
• While advances in compact generators, faster purification methods, and regional production hubs could eventually ease these pressures, the fundamental time-sensitive nature of short-lived isotopes remains a significant restraint on the widespread adoption and growth of the radiopharmaceuticals market

Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope

The market is segmented on the basis isotope, sources, therapeutic application, vector type, and end user.

• By Isotope

On the basis of isotope type, the market is segmented into beta emitters and alpha emitters. In 2025, the beta emitters segment is expected to dominate the market with the 83.70% market share, owing to the widespread clinical adoption of isotopes such as Lutetium-177 (Lu-177) and Yttrium-90 (Y-90) for treating neuroendocrine tumors, liver cancer, and prostate cancer. Beta emitters are preferred for their relatively longer half-lives, established safety profiles, and compatibility with existing clinical workflows.

The beta emitters segment is projected to witness the fastest growth rate of 11.1% from 2025 to 2032, driven by increasing usage of Actinium-225 (Ac-225) and Lead-212 (Pb-212) in advanced cancer treatments. Alpha emitters offer high linear energy transfer (LET) and greater tumor-killing efficacy with minimal collateral damage, making them highly suitable for resistant and metastatic cancers.

• By Sources

On the basis of sources, the market is categorized into reactor-produced isotopes, generator-produced isotopes, and others. In 2025, reactor-produced isotopes will lead the market due to the high-volume supply and broad availability of key beta emitters such as Lu-177 and Iodine-131.

However, reactor-produced isotopes are expected to be the fastest-growing segment, propelled by increasing demand for isotopes like Pb-212 and Ra-223, which require decentralized and near-patient production. The rise of on-site generators also aligns with the growing interest in alpha therapies and short-lived radiopharmaceuticals.

• By Therapeutic Application

On therapeutic application, the market is segmented into oncology and others. In 2025, oncology dominates the market, as radiopharmaceuticals play a central role in targeted therapies for prostate cancer, neuroendocrine tumors, and lymphoma. The increasing success of PSMA-targeted and PRRT-based therapies reinforces the leadership of oncology in this space.

The oncology segment includes cardiovascular, endocrine, and neurological disorders and is anticipated to witness steady growth with the development of novel radioligands and expansion into non-oncologic indications.

• By Vector Type

On the basis of vector type, the market is segmented into small molecule ligands, peptides, monoclonal antibodies, and others. In 2025, small molecule ligands are expected to hold the largest market share due to their rapid tissue penetration and widespread use in PSMA and somatostatin-targeted therapies.

Small molecule ligands are poised for significant growth during the forecast period due to advances in conjugation technologies and their ability to offer enhanced tumor selectivity, longer circulation times, and improved binding efficiency. These vectors are especially critical for alpha emitter therapies where precision is paramount.

• By End User

On the basis of, the market is segmented by end user into hospitals, radiopharmacies, and research institutes. In 2025, hospitals will account for the largest share, driven by increasing patient access to nuclear medicine, growth of theranostic departments, and strong reimbursement frameworks in developed countries.

The radiopharmacies segment is expected to grow rapidly due to the rising demand for centralized and decentralized compounding of radiopharmaceuticals, especially those with short half-lives. Research institutes will continue to play a vital role in innovation and clinical trials, particularly for next-generation isotopes like Terbium-161 and Actinium-225.

Alpha and Beta Emitters Based Radiopharmaceuticals Market Regional Analysis

• U.S. remains a global leader in the Alpha and Beta Emitters Based Radiopharmaceuticals Market, with a projected CAGR of 12.8% in 2025. Growth is driven by the country’s high incidence of cancer, rapid adoption of targeted radionuclide therapies, and ongoing advancements in precision medicine.
• Robust federal funding for nuclear medicine research, strong clinical trial infrastructure, and strategic collaborations between leading biotech firms, academic institutions, and the Department of Energy are accelerating innovation in therapeutic isotopes. Additionally, domestic production of key isotopes like Actinium-225 and Lutetium-177 is being scaled to ensure supply-chain resilience. These dynamics firmly position the U.S. as a dominant force in both the development and commercialization of alpha and beta emitter-based radiopharmaceuticals globally

Canada Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

Canada posts double-digit growth as new cyclotron and reactor upgrades support domestic Lu-177 output, while a widening network of outpatient theranostic centres meets rising demand for precision oncology.

Mexico Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

Mexico is emerging as a promising player in the North American radiopharmaceuticals market, supported by expanding nuclear medicine capabilities and increased demand for advanced cancer therapies. The country’s growing public-private investments in oncology care, adoption of targeted alpha and beta emitter technologies, and initiatives to enhance domestic isotope production are driving market momentum. With strategic support from institutions like the Instituto Nacional de Investigaciones Nucleares (ININ), Mexico is positioning itself as a key regional hub for accessible and cost-effective radiopharmaceutical solutions

Alpha and Beta Emitters Based Radiopharmaceuticals Market Share

The alpha and beta emitters based radiopharmaceuticals market is primarily led by well-established companies, including:

• Novartis AG (Switzerland)
• Eckert & Ziegler Germany)
• ITM Isotope Technologies Munich SE (Germany)
• SHINE Technologies, LLC (U.S.)
• Actinium Pharmaceuticals, Inc. (U.S.)
• Alpha Tau Medical Ltd. (Israel)
• ARICEUM THERAPEUTICS (Germany)
• Bayer AG (Germany)
• Curium (U.S.)
• IONETIX Corporation (U.S.)
• Isotopia (Israel)
• Lantheus (U.S.)
• Lilly (U.S.)
• Niowave (U.S.)
• NMR (U.S.)
• Orano Group (Paris)
• Telix Pharmaceuticals Limited (Australia)

Latest Developments in Alpha and Beta Emitters Based Radiopharmaceuticals Market

• In May 2025, ITM Isotope Technologies Munich SE and Radiopharm Theranostics announced a supply agreement for non-carrier-added Lutetium-177 (n.c.a. 177Lu). The partnership supports Radiopharm’s clinical development of Lu-177-based therapies, including RAD 204, RAD 202, and RV01, ensuring high-quality isotope access for targeted radiopharmaceutical treatment of solid tumors in ongoing and future clinical trials
• In March 2025, the FDA approved Novartis’ Pluvicto (Lu-177 vipivotide tetraxetan) for earlier use in PSMA-positive metastatic castration-resistant prostate cancer, allowing administration after one ARPI and before chemotherapy. Based on Phase III PSMAfore trial results, Pluvicto reduced progression or death risk by 59%, doubling median radiographic progression-free survival while maintaining a favorable safety profile and expanding patient access significantly
• In March 2025, Eckert & Ziegler and AtomVie North America Radiopharma signed a North America supply agreement for non-carrier added Lutetium-177 (Theralugand). The partnership ensures a stable, high-quality Lu-177 supply for AtomVie’s CDMO radiopharmaceutical operations, supporting early-to-late-stage development worldwide and enhancing both companies' capabilities in radiopharmaceutical innovation, regulatory compliance, and patient-centered nuclear medicine solutions
• In March 2025, Eckert & Ziegler and Actinium Pharmaceuticals signed a supply agreement for high-purity Actinium-225 (Ac-225). The partnership ensures a reliable Ac-225 source to support the development of Actimab-A and other radiotherapeutic candidates targeting AML and solid tumors, strengthening Actinium’s clinical pipeline and addressing North America isotope supply challenges in precision radiopharmaceutical therapy
• In May 2024, Novartis AG announced its agreement to acquire Mariana Oncology for USD 1 billion upfront and up to USD 750 million in milestone payments. The acquisition strengthens Novartis’ radioligand therapy (RLT) pipeline with preclinical assets targeting solid tumors, including actinium-based candidate MC-339 for small cell lung cancer, and enhances its RLT research, supply, and innovation capabilities

SKU-74193